CRISPR Therapeutics vs Intellia Therapeutics vs Editas Medicine vs Beam Therapeutics
CRISPR Therapeutics
CRSPThe gene editing company with an approved product. Casgevy is the world's first CRISPR medicine, generating early revenue for sickle cell disease and beta-thalassemia. Also developing allogeneic (off-the-shelf) CAR-T cancer therapies and a Type 1 diabetes program.
Best for investors who want proven gene editing technology with an approved product and visible revenue trajectory
Strengths
+ Only gene editing company with an approved, revenue-generating product (Casgevy)
+ Strongest cash position at $4.2B — 4+ years of runway without dilution
+ Partnership with Vertex provides commercial infrastructure for Casgevy launch
+ Allogeneic CAR-T pipeline addresses a much larger market than current programs
+ Type 1 diabetes program is a long-shot moonshot with massive upside potential
Weaknesses
− Casgevy commercial ramp has been slower than expected due to treatment complexity
− Allogeneic CAR-T field has struggled broadly — competitors have failed
− Stock price already reflects Casgevy value, so pipeline must deliver for meaningful upside
− Ex vivo editing approach (cells edited outside body) is less scalable than in vivo approaches
Intellia Therapeutics
NTLAThe in vivo gene editing leader. Instead of editing cells outside the body, Intellia delivers CRISPR directly into patients via IV infusion — a fundamentally more scalable approach. Two Phase 3 programs (ATTR and HAE) with potentially historic readouts in 2026.
Best for investors who believe in vivo gene editing is the future and want exposure to potentially transformative Phase 3 catalysts in 2026
Strengths
+ Most advanced in vivo CRISPR platform — edits genes directly inside the patient's body
+ Phase 1 showed 93% TTR reduction from a single infusion in ATTR, sustained 2+ years
+ Two Phase 3 programs reading out in 2026 — double catalyst opportunity
+ In vivo approach is fundamentally more scalable than ex vivo — no cell manufacturing needed
+ If Phase 3 succeeds, NTLA-2001 becomes the first in vivo CRISPR medicine ever approved
Weaknesses
− Patient death in NTLA-2001 trial created lasting safety concerns and regulatory scrutiny
− Pre-revenue with aggressive $120M/quarter burn rate — only 2.5 years of runway
− Permanent gene editing means any long-term safety issues are irreversible
− Competing against Alnylam's reversible RNA approach that regulators may prefer
− Stock heavily discounted — market is pricing in significant probability of failure
Editas Medicine
EDITThe legacy CRISPR platform company focused on in vivo and ex vivo editing programs after multiple pipeline resets. Editas remains relevant to gene-editing investors because its IP history, cash runway, and clinical pivots often appear in CRSP vs NTLA vs BEAM comparison searches.
Best for investors who want a higher-risk, turnaround-style gene-editing exposure and are comparing the full CRISPR-era peer set.
Strengths
+ Recognized gene-editing brand with long-running CRISPR IP history
+ Lower market expectations can create asymmetric upside if a refreshed pipeline produces credible clinical data
+ Useful peer for judging how cash runway, platform focus, and execution risk separate leaders from laggards
Weaknesses
− Multiple strategic resets and program discontinuations have damaged investor confidence
− Less advanced clinical catalyst profile than CRSP, NTLA, and BEAM
− Higher dilution and execution risk unless the company proves a focused pipeline path
Beam Therapeutics
BEAMThe next-generation gene editing play. Beam uses base editing — a more precise form of gene editing that changes individual DNA letters without cutting both strands. Think of it as CRISPR 2.0. Lead program BEAM-101 is in Phase 1/2 for sickle cell disease, competing directly with Casgevy.
Best for investors who believe base editing will ultimately surpass traditional CRISPR and want early exposure to the next generation of gene editing technology
Strengths
+ Base editing is more precise than traditional CRISPR — makes single-letter changes without double-strand breaks
+ Theoretically safer profile because it doesn't cut DNA (reducing off-target insertion/deletion risks)
+ Broad platform with applications across hematology, oncology, immunology, and rare diseases
+ BEAM-101 early data shows promising fetal hemoglobin induction in sickle cell disease
+ Strong scientific pedigree — founded by David Liu, inventor of base editing
Weaknesses
− Most pipeline programs are Phase 1 or earlier — years behind CRSP and NTLA
− Must prove base editing is meaningfully better than CRISPR to justify existence as a separate company
− Sickle cell program competes directly with already-approved Casgevy — a high bar to clear
− $1.0B cash sounds strong but multiple early programs create high burn rate
− No clear path to revenue before 2028 at the earliest
Feature comparison
| Criteria | CRISPR Therapeutics (CRSP) | Intellia (NTLA) | Beam (BEAM) | Editas Medicine (EDIT) |
|---|---|---|---|---|
| Nearest catalyst | Casgevy Q1 revenue (May 2026) | Phase 3 interim data (H1 2026) | BEAM-101 update (April 2026 ASGCT) | Pipeline-reset and clinical update milestones |
| Years to potential revenue | Generating revenue now | 2-3 years if Phase 3 succeeds | 4+ years | Not visible / high uncertainty |
| Cash per share vs stock price | Cash covers ~90% of market cap | Cash covers ~55% of market cap | Cash covers ~55% of market cap | Turnaround-sensitive |
| Platform scalability | Medium (ex vivo requires cell processing) | Very high (IV infusion, no cell processing) | High (base editing applicable broadly) | Medium |
| M&A target potential | Medium (expensive given market cap) | High (in vivo platform highly desired) | High (next-gen tech attractive to pharma) | Speculative |
| Scientific moat | First-mover with approved product | Leading in vivo CRISPR platform | Proprietary base editing, IP from David Liu lab | Legacy CRISPR IP and platform experience |
Verdict
Each of these companies represents a different bet on the future of gene editing: CRSP is the safe(r) choice — you're buying a company with an approved product, $4.2B in cash, and the validation that comes from having the first CRISPR medicine in history. The risk is that Casgevy's commercial ramp disappoints and the pipeline (allo CAR-T, diabetes) is years from contributing. Buy CRSP if you want exposure to gene editing with the lowest downside risk. NTLA is the highest-conviction 2026 play — two Phase 3 readouts that could make it the first company to prove in vivo CRISPR works in large trials. The potential upside is enormous, but so is the risk: a patient death hangs over the program, cash runway is tight, and Phase 3 failure would be devastating. Buy NTLA if you believe in vivo editing is the future and you can handle extreme volatility. BEAM is the longest-term bet — base editing may ultimately prove superior to traditional CRISPR, but we won't know for years. The earliest BEAM could have a commercial product is 2028+. Buy BEAM if you're patient, believe in the science, and want the cheapest entry point into gene editing on a per-dollar-of-technology-platform basis. For most investors, a small position across all three (weighted toward CRSP for stability) provides diversified exposure to the gene editing revolution while limiting single-company risk. Editas (EDIT) belongs in the comparison set for searchers evaluating the full public gene-editing peer group, but today it screens more like a turnaround/risk-control case than a front-runner against CRSP, NTLA, or BEAM.
Sponsored
Chart both stocks side-by-side on TradingViewAffiliate link — we may earn a commission at no cost to you